1. Home
  2. VERU vs ADAG Comparison

VERU vs ADAG Comparison

Compare VERU & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VERU
  • ADAG
  • Stock Information
  • Founded
  • VERU 1971
  • ADAG 2011
  • Country
  • VERU United States
  • ADAG China
  • Employees
  • VERU N/A
  • ADAG N/A
  • Industry
  • VERU Biotechnology: Pharmaceutical Preparations
  • ADAG Biotechnology: Pharmaceutical Preparations
  • Sector
  • VERU Health Care
  • ADAG Health Care
  • Exchange
  • VERU Nasdaq
  • ADAG Nasdaq
  • Market Cap
  • VERU 85.5M
  • ADAG 90.8M
  • IPO Year
  • VERU 1990
  • ADAG 2021
  • Fundamental
  • Price
  • VERU $0.49
  • ADAG $2.01
  • Analyst Decision
  • VERU Strong Buy
  • ADAG Strong Buy
  • Analyst Count
  • VERU 2
  • ADAG 1
  • Target Price
  • VERU $4.00
  • ADAG $8.00
  • AVG Volume (30 Days)
  • VERU 1.4M
  • ADAG 94.7K
  • Earning Date
  • VERU 08-07-2025
  • ADAG 08-05-2025
  • Dividend Yield
  • VERU N/A
  • ADAG N/A
  • EPS Growth
  • VERU N/A
  • ADAG N/A
  • EPS
  • VERU N/A
  • ADAG N/A
  • Revenue
  • VERU $16,886,419.00
  • ADAG $103,204.00
  • Revenue This Year
  • VERU N/A
  • ADAG $6,488.89
  • Revenue Next Year
  • VERU N/A
  • ADAG $57.50
  • P/E Ratio
  • VERU N/A
  • ADAG N/A
  • Revenue Growth
  • VERU 134.43
  • ADAG N/A
  • 52 Week Low
  • VERU $0.45
  • ADAG $1.33
  • 52 Week High
  • VERU $1.42
  • ADAG $3.58
  • Technical
  • Relative Strength Index (RSI)
  • VERU 35.42
  • ADAG 56.27
  • Support Level
  • VERU $0.49
  • ADAG $1.87
  • Resistance Level
  • VERU $0.61
  • ADAG $2.17
  • Average True Range (ATR)
  • VERU 0.04
  • ADAG 0.18
  • MACD
  • VERU -0.01
  • ADAG 0.01
  • Stochastic Oscillator
  • VERU 2.27
  • ADAG 71.93

About VERU Veru Inc.

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.

Share on Social Networks: